UnitedHealth Group Inc (UNH) Q2 2026 Earnings Call Highlights: Strong EPS Growth Amidst Cost ...

UnitedHealth Group Inc (UNH) reports a significant rise in adjusted EPS and operating earnings, while navigating cost pressures and strategic investments in AI.

This article first appeared on GuruFocus. - Adjusted Earnings Per Share (EPS): $6.38 compared to $4.08 in the prior year. - Total Revenues: $112 billion, largely consistent with the prior year.

- Operating Earnings: $8 billion, a 55% increase year over year. - Medical Care Ratio: 86.7%, includes $860 million of net favorable prior period medical development. - Days Claims Payable: 47 days, up approximately 2.5 days from a year ago.

- Operating Cost Ratio: 12.7% for the quarter, compared to 12.3% a year ago. - Operating Cash Flows: Approximately $11 billion, or 1.9 times net income. - Share Repurchases: $4 billion for repurchases of 11.4 million shares, with total expected repurchases of at least $5 billion in 2026.

- Dividend: $2.1 billion returned to shareholders, with an annualized dividend of $9.28 per share. - Debt-to-Capital Ratio: 41.2% at the end of the quarter, with a target of approximately 40% by the end of 2026. - Full Year 2026 Adjusted EPS Guidance: $19.50 to $20.

- Full Year Operating Earnings Outlook: UnitedHealthcare at least $12 billion, Optum Health at least $2.2 billion. - Full Year Medical Care Ratio Expectation: 88.1%, plus or minus 25 basis points.

Release Date: July 16, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points - UnitedHealth Group Inc (NYSE:UNH) reported a significant increase in adjusted earnings per share, reaching $6.38 compared to $4.08 in the prior year.

- Optum Health is showing positive momentum with improved care management and greater operating discipline. - The company is making substantial investments in AI technology to enhance service interactions, reduce administrative burdens, and support better decision-making. - UnitedHealth Group Inc (NYSE:UNH) has committed to eliminating 30% of prior authorization volume by the end of the year, aiming to simplify processes and improve consumer experiences.

- Optum Rx continues to perform well, with high customer retention rates and a shift towards transparency and fee-based services. Negative Points - The commercial benefits business is experiencing higher-than-expected cost trends, particularly due to the No Surprises Act and aggressive billing practices.

- Medicaid margins are expected to remain pressured for 2026, with ongoing challenges in aligning reimbursement rates with medical cost trends. - Medical cost trends in Medicare are running above historical levels, although slightly below initial expectations for 2026. - The IDR process under the No Surprises Act is contributing to increased costs, with significant arbitration cases brought by a few entities.

- The commercial margin recovery is expected to take longer than originally anticipated, extending the timeframe for full margin recovery past 2027.